O38 Anagrelid in the treatment of essential thrombocytemia a single institution experience

✍ Scribed by M. Hrubiško; Z. Štefániková; M. Mistrík

• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 46 KB
• Volume: 21
• Category: Article
• ISSN: 0268-960X
• DOI: 10.1016/s0268-960x(07)70055-3

✦ Synopsis

The presence of T315I mutation was confirmed by PCR-RFLP. Clonal alterations were assessed by standard cytogenetic techniques. Three different mutations (c.730A>G, c.749G>A and c.944C>T resulting in aa. exchange M244V, G250E, T315I respectively) in 5 patients were identified. Sequencing of aa. 325 505 of BCR-ABL KD is in progress. Extra Ph-chromosome was detected in 7 patients, ACA was present altogether in 11 patients. In summary, BCR-ABL KD mutations and clonal evolution are common in imatinib resistant CML patients. Early detection of emerging mutant clones may guide therapeutic decisions, because the degree of imatinib resistance varies among different mutants.

O38 Anagrelid in the treatment of essential thrombocytemia a single institution experience